Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
272
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

Ahmed Sawasa Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Helen Maa Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-0416-5115View further author information
ORCID Icon,
John Kuruvillab Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, CanadaORCID Iconhttps://orcid.org/0000-0002-6117-320XView further author information
ORCID Icon,
Jennifer K. Luea Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Changchun Denga Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Enrica Marchia Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Francesca Montanaria Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Bin Chenga Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USAView further author information
,
Kerry J. Savagec BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, CanadaView further author information
,
Diego Villac BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0002-4625-3009View further author information
ORCID Icon,
Michael Crumpb Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, CanadaView further author information
,
Joseph M. Connorsc BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, CanadaView further author information
&
Owen A. O’Connord Division of Hematology and Oncology, University of Virginia Cancer Center, Charlottesville, VA, USACorrespondence[email protected]
View further author information
 show all
Pages 3014-3017 | Received 01 Jun 2020, Accepted 04 Jul 2020, Published online: 28 Jul 2020

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
  • Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. 2017;92(9):879–884.
  • Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531–2533.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
  • Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566.
  • O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1–2 trial. Lancet Oncol. 2018;19(2) :257–266.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
  • Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol. 2017;8(10):293–302.
  • Shindiapina P, Alinari L. Pembrolizumab and its role in relapsed/refractory classical Hodgkin’s lymphoma: evidence to date and clinical utility. Ther Adv Hematol. 2018;9(4):89–105.
  • Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439.
  • Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
  • Kuruvilla J, Ramchandren R, Santoro A, et al. KEYNOTE-204: randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). J Clin Oncol. 2020;38(15):8005.
  • Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194.
  • Diefenbach CS, Hong F, Ambinder R, et al. Extended follow‐up of a phase I trial of ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: a trial of the ECOG-ACRIN research group. Hematol Oncol. 2019;37(S2):123–124.
  • LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.